drugset / Trial / NCT01636024

To Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ascending Doses of Inhaled AZD7594

NCT01636024

Phase 1 Completed 73 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindBasic science

Summary

The purpose of this study is to evaluate the safety profile and look at levels of AZD7594 and biomarkers in blood when the drug is administered inhaled to healthy subjects

Timeline

Start
2012-09
Primary completion
2013-06
Completion
2013-06

Drugs

EvaluationDrugModalityDoseRoute
Subject VELSECORAT Other / unclassified Inhaled

Indications

No indication recorded.